Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Matthew W Hruska"'
Autor:
Mary Ann Mascelli, Matthew W Hruska, Sam Liao, Lori Liao, Patrick Davies, Jennifer Kong, Douglas A Marsteller
Purpose To characterize the pharmacokinetics (PK) of naloxegol in paediatric subjects (≥ 6 months to Methods Subjects in three age groups (≥12 to Results Naloxegol exhibits comparable PK characteristics in paediatric and adult subjects. Neither a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af194453aa00bdf73d36922114faf7c
https://doi.org/10.21203/rs.3.rs-2612997/v1
https://doi.org/10.21203/rs.3.rs-2612997/v1
Autor:
Li, Zhu, Roger J, Brüggemann, Jonathan, Uy, Angela, Colbers, Matthew W, Hruska, Ellen, Chung, Karen, Sims, Blisse, Vakkalagadda, Xiaohui, Xu, Ron H N, van Schaik, David M, Burger, Richard J, Bertz
Publikováno v:
Journal of clinical pharmacology. 57(2)
Voriconazole, a broad-spectrum triazole antifungal agent, is metabolized by cytochrome P450 (CYP) 2C19 and, to a lesser extent, by CYP3A. Genetic polymorphism of CYP2C19 not only plays a prominent role in its disposition but may also influence potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c0ee46009db59ad4b616a2e202ee573d
https://pubmed.ncbi.nlm.nih.gov/27432796
https://pubmed.ncbi.nlm.nih.gov/27432796
Autor:
Matthew W. Hruska, Reginald F. Frye, Janet A. Amico, Taimour Y. Langaee, Robert E. Ferrell, S. M. Fitzgerald
Publikováno v:
British Journal of Clinical Pharmacology. 59:70-79
Aims Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8. The anti-infective drug trimethoprim has been shown in vitro t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf3bf8b9003f7016912896c377d28a8
https://doi.org/10.1111/j.1365-2125.2005.02263.x
https://doi.org/10.1111/j.1365-2125.2005.02263.x
Autor:
Reginald F. Frye, Merrill J. Egorin, Theodore F. Lagattuta, Sara M. Fitzgerald, Matthew W. Hruska
Publikováno v:
Clinical Pharmacology & Therapeutics. 76:323-329
Objective Imatinib is a potent inhibitor of the Bcr-Abl and c-kit tyrosine kinases and is approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia and gastrointestinal stromal tumors. Because imatinib is predomina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a37a5d421677dfdaa764a1996cc9b7
https://doi.org/10.1016/j.clpt.2004.06.007
https://doi.org/10.1016/j.clpt.2004.06.007
Autor:
Matthew W. Hruska, Reginald F. Frye
Publikováno v:
Journal of Chromatography B. 803:317-320
Rosiglitazone is a thiazolidinedione antihyperglycemic drug used in the treatment of type 2 diabetes mellitus. Rosiglitazone is extensively metabolized by cytochrome P450 2C8 and so may have some utility as an in vivo probe for this enzyme. A liquid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49647cd6e79c1e0228e675de117e738d
https://doi.org/10.1016/j.jchromb.2004.01.010
https://doi.org/10.1016/j.jchromb.2004.01.010
Autor:
Matthew W, Hruska, Robert, Adamczyk, Elizabeth, Colston, Michael, Hesney, Michele, Stonier, Heather, Myler, Richard, Bertz
Publikováno v:
British journal of clinical pharmacology. 80(3)
This open label study was conducted to assess the effect of renal impairment (RI) on the pharmacokinetics (PK) of peginterferon lambda-1a (Lambda).Subjects (age 18-75 years, BMI 18-35 kg m(-2) ) were enrolled into one of five renal function groups: n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9c9f749c6dc4f81287a2efc12360c14
https://pubmed.ncbi.nlm.nih.gov/25807956
https://pubmed.ncbi.nlm.nih.gov/25807956
Publikováno v:
Clinical chemistry. 50(12)
The cytochrome P450 enzymes CYP2C8 and CYP2C9 play important roles in drug metabolism (1)(2)(3). Single-nucleotide polymorphisms that have been identified in the genes encoding for these enzymes may contribute to variability in drug response through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd0d9c003673ca5a077cf10c574ec43f
https://pubmed.ncbi.nlm.nih.gov/15563491
https://pubmed.ncbi.nlm.nih.gov/15563491
Autor:
Matthew W. Hruska, Reginald F. Frye
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 807(2)
Trimethoprim is an anti-infective agent used in the treatment of urinary and respiratory tract infections and mild to moderate pneumocystis carinii pneumonia. Trimethoprim is also a selective in vitro inhibitor of cytochrome P450 2C8 and may have uti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d5e79352a24cb673dc3b16a312ee74
https://pubmed.ncbi.nlm.nih.gov/15203044
https://pubmed.ncbi.nlm.nih.gov/15203044
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P35-P35
Background/Aims The objective of this study was to investigate the effect of St. John's wort (SJW) administration on rosiglitazone metabolism in healthy subjects genotyped for CYP2C8 polymorphisms. Methods This fixed-sequence design study involved tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3ba1cae51d4a9aece83669da0874c35
https://doi.org/10.1016/j.clpt.2004.12.026
https://doi.org/10.1016/j.clpt.2004.12.026
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P36-P36
Background/Aims The purpose of this study was to investigate the effect of the CYP2C8 genetic polymorphisms CYP2C8*2, CYP2C8*3, and CYP2C8*4 on the pharmacokinetics of rosiglitazone, a PPARγ agonist and CYP2C8 substrate. Methods This single dose pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7098f3cea36a5b0b590f1b9723e44831
https://doi.org/10.1016/j.clpt.2004.12.029
https://doi.org/10.1016/j.clpt.2004.12.029